# Russell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 8 | 6.9 | 116.2 | (50.0-229.0) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 1.7 | 295.9 | (95.4-690.6) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 6.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 3.1 | nc | (nc-nc) |  | Male | 12 | 23.9 | 50.2 | (25.9-87.7) |
| Female | 2 | 2.8 | nc | (nc-nc) |  | Female | 24 | 22.2 | 108.0 | (69.2-160.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

265

# Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 6.2 | 144.9 | (66.1-275.1) |  | Male | 4 | 4.5 | nc | (nc-nc) |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 1 | 3.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 3 | 4.0 | nc | (nc-nc) |
| Female | 34 | 29.1 | 117.0 | (81.0-163.5) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 7.5 | 119.2 | (54.4-226.4) |  |  |  |  |  |  |
| Female | 7 | 6.8 | 102.4 | (41.0-211.1) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 1.8 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 25 | 25.5 | 98.2 | (63.5-145.0) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 4.0 | nc | (nc-nc) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 0 | 2.2 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 1.0 | nc | (nc-nc) |  | Male | 3 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 2.8 | 181.4 | (58.4-423.3) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 6 | 6.2 | 96.4 | (35.2-209.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 9 | 6.4 | 139.9 | (63.8-265.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 11.6 | 86.1 | (41.2-158.4) |  | Male | 89 | 92.3 | 96.4 | (77.4-118.6) |
| Female | 10 | 11.7 | 85.5 | (40.9-157.2) |  | Female | 84 | 92.1 | 91.2 | (72.8-113.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

266

# Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 36 | 38.8 | 92.7 | (64.9-128.3) |  | Male | 26 | 25.7 | 101.1 | (66.0-148.1) |
| Female | 11 | 15.9 | 69.4 | (34.6-124.2) |  | Female | 25 | 23.6 | 106.1 | (68.6-156.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 7.7 | 117.6 | (53.6-223.2) |  | Male | 4 | 7.4 | nc | (nc-nc) |
| Female | 5 | 7.2 | 69.4 | (22.4-161.9) |  | Female | 7 | 6.8 | 103.5 | (41.5-213.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.2 | nc | (nc-nc) |  | Male | 36 | 22.8 | 158.2 | (110.8-219.0) |
| Female | 192 | 172.7 | 111.2 | (96.0-128.1) |  | Female | 21 | 21.4 | 98.1 | (60.7-149.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 16 | 18.1 | 88.3 | (50.5-143.5) |
| Female | 4 | 6.3 | nc | (nc-nc) |  | Female | 14 | 8.9 | 156.9 | (85.7-263.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 49 | 43.2 | 113.3 | (83.8-149.8) |  |  |  |  |  |  |
| Female | 47 | 48.6 | 96.7 | (71.1-128.6) |  | Female | 12 | 16.0 | 75.0 | (38.7-131.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 18 | 10.4 | 172.5 | (102.2-272.7) |  | Male | 10 | 13.3 | 75.4 | (36.1-138.7) |
| Female | 4 | 3.0 | nc | (nc-nc) |  | Female | 20 | 15.5 | 129.3 | (78.9-199.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 3.6 | 140.3 | (45.2-327.5) |  | Male | 162 | 139.1 | 116.4 | (99.2-135.8) |
| Female | 8 | 3.4 | 238.2 | (102.6-469.4) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 31 | 21.4 | 145.0 | (98.5-205.8) |  | Male | 16 | 9.1 | 175.4 | (100.2-284.9) |
| Female | 17 | 13.8 | 123.5 | (71.9-197.8) |  | Female | 3 | 6.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 5.8 | 121.4 | (48.6-250.2) |  | Male | 6 | 6.4 | 94.2 | (34.4-205.1) |
| Female | 4 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 18 | 15.8 | 113.6 | (67.3-179.5) |  | Male | 13 | 10.3 | 126.1 | (67.1-215.6) |
| Female | 15 | 12.9 | 116.1 | (64.9-191.4) |  | Female | 36 | 34.4 | 104.6 | (73.2-144.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 18 | 13.3 | 135.4 | (80.2-214.0) |  |  |  |  |  |  |
| Female | 4 | 4.8 | nc | (nc-nc) |  | Female | 44 | 39.5 | 111.4 | (80.9-149.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 72 | 70.2 | 102.6 | (80.3-129.2) |  | Male | 602 | 523.8 | 114.9 | (105.9-124.5) |
| Female | 93 | 81.6 | 114.0 | (92.0-139.7) |  | Female | 631 | 591.4 | 106.7 | (98.5-115.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

267

# Salisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 9.5 | 136.4 | (72.6-233.3) |  | Male | 12 | 6.4 | 188.3 | (97.2-328.9) |
| Female | 3 | 3.4 | nc | (nc-nc) |  | Female | 3 | 5.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 5 | 5.6 | 89.7 | (28.9-209.4) |
| Female | 45 | 40.1 | 112.2 | (81.8-150.1) |  | Female | 11 | 4.7 | 232.9 | (116.1-416.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 4.8 | 231.5 | (115.4-414.3) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 0 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 18 | 10.8 | 167.1 | (99.0-264.0) |  |  |  |  |  |  |
| Female | 15 | 10.3 | 145.6 | (81.4-240.1) |  | Female | 8 | 3.6 | 221.0 | (95.2-435.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 2 | 3.3 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 4 | 3.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 33 | 37.7 | 87.4 | (60.2-122.8) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 5.5 | 199.1 | (99.2-356.2) |  | Male | 0 | 2.3 | nc | (nc-nc) |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.8 | nc | (nc-nc) |  | Male | 0 | 2.5 | nc | (nc-nc) |
| Female | 3 | 2.7 | nc | (nc-nc) |  | Female | 2 | 7.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 11 | 9.4 | 116.6 | (58.1-208.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 17.9 | 112.0 | (68.4-173.0) |  | Male | 147 | 133.2 | 110.4 | (93.2-129.7) |
| Female | 28 | 18.7 | 149.4 | (99.3-216.0) |  | Female | 158 | 132.2 | 119.5 | (101.6-139.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

268

# Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 1 | 4.4 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 6.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.1 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 14 | 22.5 | 62.1 | (33.9-104.2) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 9 | 14.5 | 62.2 | (28.4-118.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

269

# Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 31 | 24.3 | 127.4 | (86.6-180.9) |  | Male | 26 | 15.8 | 164.5 | (107.4-241.0) |
| Female | 7 | 8.9 | 79.0 | (31.7-162.9) |  | Female | 22 | 12.4 | 176.9 | (110.8-267.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 4.5 | 200.3 | (91.4-380.3) |  | Male | 3 | 4.7 | nc | (nc-nc) |
| Female | 5 | 3.9 | 129.0 | (41.6-301.0) |  | Female | 1 | 3.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  | Male | 18 | 13.9 | 129.6 | (76.7-204.8) |
| Female | 105 | 99.4 | 105.7 | (86.4-127.9) |  | Female | 16 | 12.0 | 133.7 | (76.4-217.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 11.6 | 95.0 | (47.3-169.9) |
| Female | 0 | 3.3 | nc | (nc-nc) |  | Female | 6 | 5.0 | 118.9 | (43.4-258.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 21 | 27.0 | 77.7 | (48.1-118.8) |  |  |  |  |  |  |
| Female | 25 | 26.9 | 93.0 | (60.2-137.3) |  | Female | 8 | 9.0 | 88.8 | (38.2-175.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 6.7 | 74.1 | (23.9-173.0) |  | Male | 12 | 8.4 | 142.6 | (73.6-249.1) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 9 | 8.6 | 104.7 | (47.8-198.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 111 | 92.4 | 120.1 | (98.8-144.6) |
| Female | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 13.5 | 74.1 | (35.5-136.3) |  | Male | 7 | 5.7 | 122.1 | (48.9-251.6) |
| Female | 4 | 7.8 | nc | (nc-nc) |  | Female | 4 | 3.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 3.7 | nc | (nc-nc) |  | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 15 | 9.5 | 157.8 | (88.2-260.2) |  | Male | 4 | 6.0 | nc | (nc-nc) |
| Female | 5 | 7.0 | 71.7 | (23.1-167.4) |  | Female | 11 | 17.4 | 63.3 | (31.6-113.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 8.6 | 69.9 | (25.5-152.2) |  |  |  |  |  |  |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 22 | 23.0 | 95.5 | (59.8-144.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 21 | 44.9 | 46.8 | (28.9-71.5) |  | Male | 355 | 330.9 | 107.3 | (96.4-119.1) |
| Female | 44 | 46.9 | 93.9 | (68.2-126.1) |  | Female | 324 | 331.4 | 97.8 | (87.4-109.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

270

# Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 40 | 34.0 | 117.7 | (84.1-160.3) |  | Male | 14 | 21.4 | 65.5 | (35.8-109.9) |
| Female | 20 | 12.7 | 157.1 | (95.9-242.6) |  | Female | 16 | 17.1 | 93.8 | (53.6-152.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 5.8 | nc | (nc-nc) |  | Male | 4 | 6.3 | nc | (nc-nc) |
| Female | 9 | 5.2 | 172.4 | (78.7-327.3) |  | Female | 3 | 5.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 22 | 18.8 | 117.2 | (73.4-177.5) |
| Female | 144 | 131.9 | 109.2 | (92.1-128.5) |  | Female | 17 | 16.6 | 102.1 | (59.4-163.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 22 | 14.7 | 149.4 | (93.6-226.2) |
| Female | 4 | 4.4 | nc | (nc-nc) |  | Female | 7 | 6.9 | 101.7 | (40.7-209.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 43 | 36.5 | 117.7 | (85.2-158.5) |  |  |  |  |  |  |
| Female | 40 | 38.1 | 104.9 | (74.9-142.8) |  | Female | 8 | 12.1 | 66.1 | (28.4-130.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 14 | 8.9 | 157.6 | (86.1-264.4) |  | Male | 8 | 11.4 | 70.2 | (30.2-138.3) |
| Female | 4 | 2.5 | nc | (nc-nc) |  | Female | 12 | 12.4 | 97.0 | (50.1-169.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 2.4 | 211.8 | (68.2-494.2) |  | Male | 97 | 117.6 | 82.5 | (66.9-100.7) |
| Female | 1 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 27 | 17.5 | 153.9 | (101.4-224.0) |  | Male | 8 | 7.8 | 102.6 | (44.2-202.1) |
| Female | 11 | 10.7 | 102.6 | (51.2-183.6) |  | Female | 2 | 4.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 4.9 | 122.6 | (44.8-266.9) |  | Male | 9 | 3.8 | 239.8 | (109.4-455.2) |
| Female | 3 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 18 | 12.9 | 139.3 | (82.5-220.2) |  | Male | 11 | 7.7 | 142.6 | (71.1-255.1) |
| Female | 5 | 9.8 | 51.2 | (16.5-119.6) |  | Female | 18 | 23.0 | 78.3 | (46.4-123.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 14 | 11.0 | 126.7 | (69.2-212.7) |  |  |  |  |  |  |
| Female | 4 | 3.8 | nc | (nc-nc) |  | Female | 27 | 30.4 | 88.9 | (58.6-129.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 67 | 61.3 | 109.2 | (84.6-138.7) |  | Male | 468 | 439.7 | 106.4 | (97.0-116.5) |
| Female | 90 | 66.3 | 135.8 | (109.2-167.0) |  | Female | 495 | 454.2 | 109.0 | (99.6-119.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

271

# Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 4 | 3.0 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 3.8 | nc | (nc-nc) |
| Female | 1 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 5 | 13.2 | 37.9 | (12.2-88.6) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 8 | 9.8 | 81.9 | (35.3-161.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

272

# Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 26 | 23.5 | 110.5 | (72.2-161.9) |  | Male | 39 | 14.8 | 264.1 | (187.8-361.1) |
| Female | 12 | 8.4 | 143.3 | (74.0-250.4) |  | Female | 32 | 11.2 | 284.5 | (194.6-401.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 4.1 | 122.2 | (39.4-285.3) |  | Male | 5 | 4.4 | 112.9 | (36.4-263.5) |
| Female | 3 | 3.5 | nc | (nc-nc) |  | Female | 4 | 3.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 11 | 13.0 | 84.7 | (42.2-151.6) |
| Female | 98 | 90.1 | 108.8 | (88.3-132.6) |  | Female | 9 | 11.1 | 81.4 | (37.1-154.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 10.4 | 163.7 | (95.3-262.1) |
| Female | 1 | 2.9 | nc | (nc-nc) |  | Female | 6 | 4.6 | 129.9 | (47.4-282.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 21 | 25.5 | 82.3 | (50.9-125.9) |  |  |  |  |  |  |
| Female | 18 | 25.4 | 71.0 | (42.0-112.2) |  | Female | 8 | 8.2 | 98.1 | (42.2-193.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 6.2 | 96.3 | (35.2-209.7) |  | Male | 8 | 7.9 | 100.7 | (43.3-198.4) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 9 | 8.1 | 110.6 | (50.5-210.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 63 | 83.1 | 75.8 | (58.3-97.0) |
| Female | 2 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 12.3 | 48.8 | (17.8-106.3) |  | Male | 7 | 5.4 | 129.0 | (51.7-265.8) |
| Female | 6 | 7.2 | 83.3 | (30.4-181.4) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.4 | nc | (nc-nc) |  | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 9.0 | 100.2 | (45.7-190.1) |  | Male | 2 | 5.3 | nc | (nc-nc) |
| Female | 8 | 6.5 | 122.9 | (52.9-242.2) |  | Female | 19 | 15.2 | 124.7 | (75.0-194.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 7.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 14 | 20.6 | 67.8 | (37.1-113.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 37 | 42.7 | 86.7 | (61.0-119.5) |  | Male | 295 | 306.7 | 96.2 | (85.5-107.8) |
| Female | 47 | 43.9 | 107.1 | (78.7-142.5) |  | Female | 321 | 304.4 | 105.5 | (94.2-117.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

273

# Seekonk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 16.7 | 113.5 | (68.3-177.2) |  | Male | 11 | 10.8 | 101.7 | (50.7-182.0) |
| Female | 2 | 5.4 | nc | (nc-nc) |  | Female | 8 | 8.0 | 100.0 | (43.1-197.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 3 | 3.2 | nc | (nc-nc) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 12 | 9.5 | 126.4 | (65.2-220.7) |
| Female | 59 | 63.0 | 93.6 | (71.3-120.8) |  | Female | 5 | 7.5 | 67.1 | (21.6-156.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 7.7 | 64.9 | (20.9-151.4) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 5 | 3.2 | 158.1 | (50.9-368.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 18.4 | 54.3 | (26.0-99.8) |  |  |  |  |  |  |
| Female | 10 | 16.7 | 59.9 | (28.7-110.2) |  | Female | 6 | 5.7 | 105.5 | (38.5-229.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 4.5 | nc | (nc-nc) |  | Male | 3 | 5.7 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 7 | 5.3 | 133.0 | (53.3-274.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 42 | 61.0 | 68.8 | (49.6-93.1) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 9.1 | 76.9 | (30.8-158.5) |  | Male | 5 | 3.9 | 127.6 | (41.1-297.8) |
| Female | 1 | 4.9 | nc | (nc-nc) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 6.5 | 108.1 | (43.3-222.8) |  | Male | 4 | 4.1 | nc | (nc-nc) |
| Female | 3 | 4.3 | nc | (nc-nc) |  | Female | 13 | 11.6 | 111.9 | (59.5-191.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 5.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 9 | 14.5 | 62.1 | (28.3-117.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 30.6 | 62.0 | (37.3-96.8) |  | Male | 170 | 223.5 | 76.1 | (65.1-88.4) |
| Female | 32 | 29.0 | 110.3 | (75.4-155.7) |  | Female | 179 | 208.7 | 85.8 | (73.7-99.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

274

# Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 19.0 | 73.8 | (40.3-123.8) |  | Male | 14 | 12.7 | 110.5 | (60.4-185.4) |
| Female | 5 | 6.4 | 78.6 | (25.3-183.4) |  | Female | 13 | 9.7 | 134.0 | (71.3-229.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.7 | nc | (nc-nc) |  | Male | 8 | 3.7 | 213.5 | (91.9-420.6) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.6 | nc | (nc-nc) |  | Male | 18 | 11.2 | 161.2 | (95.5-254.7) |
| Female | 87 | 77.4 | 112.4 | (90.1-138.7) |  | Female | 8 | 8.9 | 89.7 | (38.6-176.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 9.5 | 62.9 | (23.0-136.9) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 1 | 3.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 21.7 | 59.9 | (31.9-102.5) |  |  |  |  |  |  |
| Female | 12 | 19.8 | 60.7 | (31.3-106.0) |  | Female | 9 | 6.9 | 129.5 | (59.1-245.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.4 | nc | (nc-nc) |  | Male | 10 | 6.6 | 150.5 | (72.1-276.9) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 8 | 6.2 | 130.0 | (56.0-256.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 72 | 73.7 | 97.7 | (76.5-123.1) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 11.0 | 54.7 | (20.0-119.2) |  | Male | 3 | 4.6 | nc | (nc-nc) |
| Female | 5 | 5.9 | 84.6 | (27.3-197.4) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.0 | nc | (nc-nc) |  | Male | 4 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 7.6 | nc | (nc-nc) |  | Male | 8 | 5.0 | 160.0 | (68.9-315.4) |
| Female | 4 | 5.2 | nc | (nc-nc) |  | Female | 30 | 14.5 | 207.3 | (139.8-295.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 7.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 12 | 17.9 | 67.1 | (34.7-117.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 13 | 35.0 | 37.1 | (19.8-63.5) |  | Male | 226 | 264.0 | 85.6 | (74.8-97.5) |
| Female | 32 | 34.0 | 94.2 | (64.4-133.0) |  | Female | 256 | 252.0 | 101.6 | (89.5-114.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

275

# Sheffield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 4.8 | 104.2 | (33.6-243.3) |  | Male | 4 | 3.0 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 3 | 2.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 2.6 | nc | (nc-nc) |
| Female | 22 | 17.2 | 128.1 | (80.2-193.9) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 5.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 4.9 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 17 | 17.3 | 98.3 | (57.3-157.5) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 2.5 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 1 | 2.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 3 | 4.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 8.7 | 57.2 | (18.4-133.6) |  | Male | 46 | 62.7 | 73.3 | (53.7-97.8) |
| Female | 16 | 8.6 | 185.5 | (106.0-301.3) |  | Female | 64 | 58.8 | 108.9 | (83.9-139.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

276

# Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 3 | 1.7 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 3 | 1.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 2 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 8 | 10.1 | 79.1 | (34.1-155.9) |  | Female | 3 | 1.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 3.0 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 16 | 10.1 | 158.5 | (90.5-257.4) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 7 | 2.4 | 289.4 | (116.0-596.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 5.0 | nc | (nc-nc) |  | Male | 41 | 36.1 | 113.6 | (81.5-154.2) |
| Female | 3 | 5.1 | nc | (nc-nc) |  | Female | 41 | 35.1 | 116.7 | (83.7-158.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

277

# Sherborn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 4.8 | 144.7 | (58.0-298.1) |  | Male | 5 | 3.2 | 157.9 | (50.9-368.5) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 3 | 2.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 21 | 18.8 | 111.8 | (69.2-170.9) |  | Female | 3 | 2.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 5.5 | 146.6 | (63.1-288.9) |  |  |  |  |  |  |
| Female | 3 | 4.7 | nc | (nc-nc) |  | Female | 3 | 1.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 3 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 20 | 18.4 | 108.9 | (66.5-168.1) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 2.7 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 1.9 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 5 | 3.3 | 149.8 | (48.3-349.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 5 | 4.3 | 116.1 | (37.4-271.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 9.0 | nc | (nc-nc) |  | Male | 65 | 66.2 | 98.2 | (75.8-125.2) |
| Female | 7 | 8.3 | 84.7 | (34.0-174.6) |  | Female | 62 | 60.3 | 102.9 | (78.9-131.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

278

# Shirley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 6.4 | 124.7 | (53.7-245.8) |  | Male | 4 | 4.9 | nc | (nc-nc) |
| Female | 5 | 2.0 | 253.9 | (81.8-592.4) |  | Female | 0 | 3.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 4.3 | nc | (nc-nc) |
| Female | 23 | 24.3 | 94.5 | (59.9-141.8) |  | Female | 0 | 2.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 3.6 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 7.9 | 164.6 | (87.5-281.4) |  |  |  |  |  |  |
| Female | 9 | 6.2 | 146.2 | (66.7-277.5) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 3 | 1.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 24 | 24.8 | 96.7 | (61.9-143.9) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 4.2 | 167.6 | (67.2-345.4) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 2.9 | nc | (nc-nc) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 4 | 4.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 2.5 | 314.6 | (135.5-619.9) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 12 | 5.5 | 216.3 | (111.7-377.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 23 | 11.8 | 195.2 | (123.7-292.9) |  | Male | 110 | 95.1 | 115.7 | (95.1-139.5) |
| Female | 15 | 10.5 | 142.8 | (79.8-235.5) |  | Female | 86 | 79.2 | 108.6 | (86.8-134.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

279

# Shrewsbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 43 | 36.3 | 118.4 | (85.7-159.5) |  | Male | 11 | 23.9 | 46.1 | (23.0-82.4) |
| Female | 10 | 13.5 | 74.2 | (35.5-136.5) |  | Female | 20 | 19.3 | 103.4 | (63.1-159.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 7.1 | 127.1 | (58.0-241.2) |  | Male | 10 | 6.9 | 144.2 | (69.1-265.3) |
| Female | 3 | 6.1 | nc | (nc-nc) |  | Female | 5 | 5.7 | 87.6 | (28.2-204.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 32 | 21.2 | 150.9 | (103.2-213.1) |
| Female | 151 | 147.4 | 102.5 | (86.8-120.2) |  | Female | 12 | 18.1 | 66.5 | (34.3-116.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 16.8 | 77.5 | (41.2-132.6) |
| Female | 3 | 5.3 | nc | (nc-nc) |  | Female | 5 | 7.5 | 66.9 | (21.5-156.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 38 | 40.7 | 93.3 | (66.0-128.1) |  |  |  |  |  |  |
| Female | 34 | 41.8 | 81.3 | (56.3-113.7) |  | Female | 12 | 13.3 | 90.3 | (46.6-157.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 14 | 9.6 | 145.8 | (79.7-244.7) |  | Male | 13 | 12.3 | 105.6 | (56.2-180.6) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 8 | 13.2 | 60.8 | (26.2-119.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 3.0 | nc | (nc-nc) |  | Male | 130 | 125.8 | 103.3 | (86.3-122.7) |
| Female | 5 | 2.4 | 204.3 | (65.8-476.7) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 30 | 19.9 | 150.6 | (101.6-215.1) |  | Male | 5 | 8.6 | 58.5 | (18.8-136.5) |
| Female | 11 | 11.6 | 94.5 | (47.1-169.0) |  | Female | 2 | 5.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 5.3 | nc | (nc-nc) |  | Male | 7 | 5.0 | 138.7 | (55.6-285.7) |
| Female | 0 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 14.7 | 81.5 | (42.1-142.4) |  | Male | 15 | 9.4 | 160.0 | (89.5-263.9) |
| Female | 9 | 11.0 | 81.6 | (37.2-154.8) |  | Female | 17 | 28.3 | 60.1 | (35.0-96.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 9 | 12.2 | 73.8 | (33.7-140.1) |  |  |  |  |  |  |
| Female | 1 | 4.0 | nc | (nc-nc) |  | Female | 25 | 32.4 | 77.2 | (49.9-113.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 56 | 65.2 | 85.9 | (64.9-111.5) |  | Male | 495 | 482.7 | 102.5 | (93.7-112.0) |
| Female | 57 | 68.7 | 83.0 | (62.9-107.6) |  | Female | 425 | 499.3 | 85.1 | (77.2-93.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

280

# Shutesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 6 | 8.0 | 75.2 | (27.4-163.6) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 3 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 7.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 3 | 1.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 3.4 | nc | (nc-nc) |  | Male | 14 | 26.4 | 53.0 | (29.0-89.0) |
| Female | 1 | 3.0 | nc | (nc-nc) |  | Female | 17 | 24.5 | 69.5 | (40.5-111.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

281

# Somerset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 25 | 26.2 | 95.3 | (61.7-140.8) |  | Male | 13 | 15.8 | 82.3 | (43.8-140.7) |
| Female | 12 | 10.7 | 112.3 | (58.0-196.1) |  | Female | 8 | 12.7 | 62.9 | (27.1-123.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 4.2 | 119.8 | (38.6-279.6) |  | Male | 2 | 4.7 | nc | (nc-nc) |
| Female | 3 | 3.9 | nc | (nc-nc) |  | Female | 4 | 4.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 13 | 14.0 | 93.0 | (49.5-159.1) |
| Female | 90 | 97.5 | 92.3 | (74.2-113.5) |  | Female | 12 | 13.2 | 90.6 | (46.8-158.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 10.5 | 76.5 | (32.9-150.7) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 7 | 5.3 | 131.7 | (52.7-271.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 25 | 27.5 | 91.0 | (58.9-134.4) |  |  |  |  |  |  |
| Female | 30 | 32.0 | 93.9 | (63.3-134.0) |  | Female | 10 | 9.1 | 109.9 | (52.6-202.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 6.5 | 76.5 | (24.6-178.4) |  | Male | 12 | 8.6 | 139.5 | (72.0-243.7) |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 10 | 10.6 | 94.7 | (45.3-174.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 1.6 | nc | (nc-nc) |  | Male | 88 | 84.4 | 104.3 | (83.6-128.4) |
| Female | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 16 | 12.6 | 126.6 | (72.3-205.6) |  | Male | 11 | 5.9 | 186.7 | (93.1-334.1) |
| Female | 9 | 8.2 | 109.8 | (50.1-208.4) |  | Female | 5 | 4.1 | 121.9 | (39.3-284.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.6 | nc | (nc-nc) |  | Male | 7 | 2.4 | 290.3 | (116.3-598.2) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 9.7 | 113.4 | (56.5-202.8) |  | Male | 3 | 5.3 | nc | (nc-nc) |
| Female | 12 | 7.9 | 152.0 | (78.5-265.6) |  | Female | 23 | 15.5 | 148.7 | (94.2-223.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 7.9 | 88.3 | (35.4-181.9) |  |  |  |  |  |  |
| Female | 1 | 3.0 | nc | (nc-nc) |  | Female | 26 | 22.0 | 118.4 | (77.3-173.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 52 | 46.2 | 112.5 | (84.0-147.5) |  | Male | 335 | 324.4 | 103.3 | (92.5-114.9) |
| Female | 39 | 52.4 | 74.5 | (53.0-101.8) |  | Female | 332 | 350.4 | 94.7 | (84.8-105.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

282

# Somerville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 43 | 50.6 | 85.0 | (61.5-114.5) |  | Male | 31 | 36.8 | 84.2 | (57.2-119.5) |
| Female | 20 | 20.1 | 99.6 | (60.8-153.9) |  | Female | 17 | 36.0 | 47.2 | (27.5-75.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 12.1 | 66.1 | (28.5-130.3) |  | Male | 12 | 9.8 | 122.3 | (63.1-213.7) |
| Female | 14 | 10.5 | 133.6 | (73.0-224.2) |  | Female | 11 | 8.6 | 128.5 | (64.0-229.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 37 | 32.6 | 113.4 | (79.9-156.4) |
| Female | 190 | 224.0 | 84.8 | (73.2-97.8) |  | Female | 19 | 28.4 | 66.9 | (40.3-104.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 29 | 24.9 | 116.4 | (78.0-167.2) |
| Female | 8 | 10.2 | 78.7 | (33.9-155.0) |  | Female | 8 | 11.6 | 69.2 | (29.8-136.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 55 | 58.2 | 94.5 | (71.2-123.0) |  |  |  |  |  |  |
| Female | 56 | 62.6 | 89.5 | (67.6-116.2) |  | Female | 22 | 21.3 | 103.4 | (64.8-156.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 13.6 | 88.4 | (45.6-154.4) |  | Male | 21 | 17.4 | 120.9 | (74.8-184.9) |
| Female | 6 | 3.9 | 155.8 | (56.9-339.2) |  | Female | 21 | 19.6 | 107.0 | (66.2-163.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 15 | 7.7 | 194.7 | (108.9-321.1) |  | Male | 151 | 179.1 | 84.3 | (71.4-98.9) |
| Female | 4 | 6.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 34 | 29.8 | 114.0 | (79.0-159.3) |  | Male | 17 | 12.2 | 139.7 | (81.3-223.7) |
| Female | 23 | 18.0 | 128.0 | (81.1-192.0) |  | Female | 11 | 7.9 | 138.9 | (69.3-248.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 10 | 7.6 | 132.4 | (63.4-243.6) |  | Male | 7 | 16.8 | 41.8 | (16.7-86.1) |
| Female | 2 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 19 | 22.7 | 83.8 | (50.4-130.9) |  | Male | 19 | 17.5 | 108.5 | (65.3-169.4) |
| Female | 19 | 17.8 | 106.6 | (64.2-166.5) |  | Female | 53 | 58.8 | 90.1 | (67.5-117.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 25 | 17.6 | 142.4 | (92.2-210.3) |  |  |  |  |  |  |
| Female | 13 | 6.1 | 214.2 | (113.9-366.3) |  | Female | 46 | 49.6 | 92.8 | (67.9-123.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 111 | 90.6 | 122.5 | (100.8-147.5) |  | Male | 706 | 714.7 | 98.8 | (91.6-106.4) |
| Female | 103 | 103.2 | 99.8 | (81.4-121.0) |  | Female | 727 | 789.6 | 92.1 | (85.5-99.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

283

# South Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 21.4 | 88.8 | (53.4-138.7) |  | Male | 22 | 13.0 | 169.3 | (106.1-256.3) |
| Female | 13 | 8.4 | 154.0 | (81.9-263.3) |  | Female | 9 | 11.1 | 80.9 | (36.9-153.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  | Male | 3 | 3.9 | nc | (nc-nc) |
| Female | 2 | 3.5 | nc | (nc-nc) |  | Female | 1 | 3.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 12 | 11.5 | 104.4 | (53.9-182.3) |
| Female | 97 | 81.5 | 119.0 | (96.5-145.2) |  | Female | 10 | 10.8 | 92.3 | (44.2-169.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 8.7 | 57.1 | (18.4-133.4) |
| Female | 5 | 2.7 | 188.2 | (60.6-439.2) |  | Female | 7 | 4.4 | 159.1 | (63.7-327.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 22 | 22.6 | 97.2 | (60.9-147.2) |  |  |  |  |  |  |
| Female | 31 | 25.5 | 121.7 | (82.7-172.7) |  | Female | 5 | 7.7 | 64.8 | (20.9-151.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 5.4 | 92.7 | (29.9-216.2) |  | Male | 5 | 7.1 | 70.8 | (22.8-165.3) |
| Female | 3 | 1.6 | nc | (nc-nc) |  | Female | 8 | 8.3 | 96.4 | (41.5-190.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 74 | 70.0 | 105.6 | (82.9-132.6) |
| Female | 0 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 10.4 | 76.6 | (33.0-151.0) |  | Male | 8 | 4.8 | 165.6 | (71.3-326.3) |
| Female | 6 | 6.8 | 88.9 | (32.4-193.4) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 8 | 2.9 | 271.4 | (116.9-534.8) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 8.0 | 62.7 | (20.2-146.3) |  | Male | 3 | 4.4 | nc | (nc-nc) |
| Female | 7 | 6.6 | 106.7 | (42.7-219.8) |  | Female | 10 | 14.7 | 67.9 | (32.5-124.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 6.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.4 | nc | (nc-nc) |  | Female | 24 | 18.5 | 129.8 | (83.2-193.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 33 | 37.7 | 87.4 | (60.2-122.8) |  | Male | 263 | 267.4 | 98.4 | (86.8-111.0) |
| Female | 37 | 42.3 | 87.5 | (61.6-120.7) |  | Female | 295 | 290.7 | 101.5 | (90.2-113.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

284

# Southampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 6.3 | 79.1 | (25.5-184.6) |  | Male | 1 | 4.4 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 2 | 3.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 3.8 | nc | (nc-nc) |
| Female | 22 | 26.6 | 82.7 | (51.8-125.2) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 7.3 | 123.0 | (56.1-233.5) |  |  |  |  |  |  |
| Female | 8 | 6.5 | 122.3 | (52.6-240.9) |  | Female | 3 | 2.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 4 | 2.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.5 | nc | (nc-nc) |  | Male | 25 | 26.7 | 93.7 | (60.6-138.3) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 3.9 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 4 | 2.0 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 1 | 5.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 7 | 6.3 | 111.4 | (44.6-229.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 11.9 | 41.8 | (13.5-97.6) |  | Male | 75 | 91.7 | 81.8 | (64.3-102.5) |
| Female | 11 | 11.7 | 94.4 | (47.1-168.9) |  | Female | 71 | 86.0 | 82.6 | (64.5-104.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

285

# Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 9.0 | 134.0 | (69.2-234.1) |  | Male | 6 | 6.3 | 95.5 | (34.9-207.9) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 4 | 4.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 5 | 1.8 | 273.4 | (88.1-638.1) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 4 | 5.5 | nc | (nc-nc) |
| Female | 45 | 39.7 | 113.3 | (82.6-151.6) |  | Female | 4 | 4.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 4.8 | 166.8 | (71.8-328.8) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 10.6 | 56.6 | (20.7-123.2) |  |  |  |  |  |  |
| Female | 13 | 9.6 | 135.0 | (71.8-230.9) |  | Female | 2 | 3.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 1 | 3.2 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 6 | 2.9 | 203.4 | (74.3-442.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 42 | 35.7 | 117.5 | (84.7-158.9) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 5.5 | 108.1 | (39.5-235.3) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 1 | 3.0 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 3 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.8 | nc | (nc-nc) |  | Male | 5 | 2.7 | 188.3 | (60.7-439.4) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 5 | 7.7 | 65.0 | (21.0-151.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 3.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 8 | 8.9 | 90.3 | (38.9-178.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 16.9 | 65.3 | (32.5-116.8) |  | Male | 138 | 129.1 | 106.9 | (89.8-126.3) |
| Female | 19 | 16.9 | 112.6 | (67.8-175.9) |  | Female | 128 | 126.6 | 101.1 | (84.4-120.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

286

# Southbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 16.8 | 112.8 | (67.9-176.1) |  | Male | 6 | 10.9 | 54.8 | (20.0-119.3) |
| Female | 9 | 6.7 | 134.1 | (61.2-254.6) |  | Female | 4 | 9.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 3 | 3.2 | nc | (nc-nc) |
| Female | 1 | 2.9 | nc | (nc-nc) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 9 | 9.7 | 92.3 | (42.1-175.3) |
| Female | 68 | 69.0 | 98.6 | (76.5-124.9) |  | Female | 10 | 8.8 | 113.5 | (54.3-208.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 7.7 | 156.3 | (80.7-273.1) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 2 | 3.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 18.7 | 101.7 | (61.2-158.8) |  |  |  |  |  |  |
| Female | 20 | 20.6 | 96.9 | (59.1-149.6) |  | Female | 6 | 6.4 | 93.6 | (34.2-203.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 4.4 | nc | (nc-nc) |  | Male | 5 | 5.7 | 87.6 | (28.2-204.4) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 3 | 6.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 43 | 58.8 | 73.1 | (52.9-98.5) |
| Female | 3 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 9.1 | 121.4 | (60.5-217.2) |  | Male | 6 | 3.9 | 152.4 | (55.6-331.7) |
| Female | 11 | 5.6 | 197.3 | (98.3-353.0) |  | Female | 5 | 2.6 | 190.3 | (61.3-444.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 2.4 | 204.6 | (65.9-477.4) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 6.8 | 87.7 | (32.0-191.0) |  | Male | 0 | 4.3 | nc | (nc-nc) |
| Female | 10 | 5.4 | 184.7 | (88.4-339.7) |  | Female | 7 | 13.1 | 53.6 | (21.5-110.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 5.6 | 106.6 | (38.9-232.1) |  |  |  |  |  |  |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 15 | 15.6 | 96.3 | (53.8-158.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 40 | 30.0 | 133.5 | (95.4-181.8) |  | Male | 220 | 223.3 | 98.5 | (85.9-112.4) |
| Female | 33 | 33.3 | 99.2 | (68.3-139.3) |  | Female | 233 | 240.1 | 97.0 | (85.0-110.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

287

# Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 10.7 | 93.4 | (44.7-171.7) |  | Male | 5 | 7.1 | 70.4 | (22.7-164.3) |
| Female | 3 | 4.0 | nc | (nc-nc) |  | Female | 4 | 5.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 2 | 6.3 | nc | (nc-nc) |
| Female | 32 | 43.1 | 74.2 | (50.8-104.8) |  | Female | 7 | 5.3 | 132.9 | (53.2-273.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 5.2 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 3 | 2.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 12.2 | 57.5 | (23.0-118.5) |  |  |  |  |  |  |
| Female | 15 | 12.3 | 122.2 | (68.4-201.6) |  | Female | 4 | 3.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 3 | 3.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 3.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 37 | 39.9 | 92.7 | (65.3-127.8) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 6.0 | 99.3 | (36.2-216.0) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 1 | 3.4 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 4 | 1.3 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 4.3 | nc | (nc-nc) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 5 | 3.1 | 159.2 | (51.3-371.4) |  | Female | 4 | 7.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 5 | 9.7 | 51.8 | (16.7-120.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 15 | 19.5 | 76.8 | (43.0-126.8) |  | Male | 116 | 146.3 | 79.3 | (65.5-95.1) |
| Female | 11 | 20.3 | 54.1 | (27.0-96.8) |  | Female | 111 | 145.6 | 76.2 | (62.7-91.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

288

# Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 13.3 | 143.1 | (86.1-223.5) |  | Male | 5 | 8.7 | 57.2 | (18.4-133.5) |
| Female | 12 | 4.5 | 268.0 | (138.3-468.2) |  | Female | 4 | 6.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 5 | 7.7 | 65.2 | (21.0-152.1) |
| Female | 45 | 50.6 | 89.0 | (64.9-119.0) |  | Female | 6 | 6.1 | 98.3 | (35.9-214.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 6.3 | 95.1 | (34.7-207.0) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 3 | 2.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 14.8 | 81.2 | (41.9-141.9) |  |  |  |  |  |  |
| Female | 17 | 13.6 | 125.2 | (72.9-200.5) |  | Female | 2 | 4.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.7 | nc | (nc-nc) |  | Male | 3 | 4.6 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 2 | 4.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 25 | 49.8 | 50.2 | (32.5-74.2) |
| Female | 2 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 7.4 | 162.1 | (83.6-283.1) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 7 | 4.0 | 175.6 | (70.4-361.9) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 14 | 5.3 | 265.9 | (145.2-446.1) |  | Male | 2 | 3.4 | nc | (nc-nc) |
| Female | 5 | 3.6 | 139.3 | (44.9-325.1) |  | Female | 3 | 9.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 4.7 | 107.0 | (34.5-249.8) |  |  |  |  |  |  |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 15 | 11.7 | 127.7 | (71.4-210.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 26 | 24.4 | 106.4 | (69.5-156.0) |  | Male | 153 | 180.8 | 84.6 | (71.7-99.1) |
| Female | 19 | 23.7 | 80.2 | (48.3-125.2) |  | Female | 166 | 169.6 | 97.9 | (83.5-113.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

289

# Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 97 | 123.0 | 78.9 | (64.0-96.2) |  | Male | 33 | 82.0 | 40.2 | (27.7-56.5) |
| Female | 40 | 49.1 | 81.5 | (58.2-111.0) |  | Female | 34 | 75.5 | 45.0 | (31.2-62.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 28 | 26.3 | 106.5 | (70.8-154.0) |  | Male | 22 | 23.5 | 93.5 | (58.6-141.5) |
| Female | 24 | 24.3 | 98.7 | (63.2-146.8) |  | Female | 17 | 21.0 | 80.9 | (47.1-129.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 8 | 3.9 | 204.7 | (88.1-403.3) |  | Male | 68 | 73.4 | 92.6 | (71.9-117.4) |
| Female | 528 | 548.2 | 96.3 | (88.3-104.9) |  | Female | 62 | 67.5 | 91.8 | (70.4-117.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 64 | 57.9 | 110.6 | (85.2-141.3) |
| Female | 31 | 20.6 | 150.8 | (102.4-214.0) |  | Female | 21 | 28.1 | 74.7 | (46.2-114.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 148 | 137.6 | 107.6 | (91.0-126.4) |  |  |  |  |  |  |
| Female | 151 | 151.2 | 99.8 | (84.5-117.1) |  | Female | 39 | 50.6 | 77.1 | (54.8-105.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 37 | 33.0 | 112.2 | (79.0-154.7) |  | Male | 42 | 42.0 | 100.1 | (72.1-135.3) |
| Female | 13 | 9.4 | 137.9 | (73.4-235.8) |  | Female | 41 | 47.8 | 85.8 | (61.6-116.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 11 | 12.4 | 88.7 | (44.2-158.6) |  | Male | 452 | 439.6 | 102.8 | (93.6-112.8) |
| Female | 15 | 11.5 | 130.3 | (72.9-215.0) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 81 | 68.4 | 118.4 | (94.0-147.1) |  | Male | 38 | 29.0 | 131.1 | (92.8-179.9) |
| Female | 47 | 43.7 | 107.5 | (79.0-143.0) |  | Female | 24 | 19.0 | 126.3 | (80.9-187.9) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 19 | 18.3 | 103.9 | (62.5-162.3) |  | Male | 13 | 21.8 | 59.5 | (31.7-101.8) |
| Female | 8 | 6.6 | 120.8 | (52.0-238.1) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 48 | 52.7 | 91.0 | (67.1-120.7) |  | Male | 14 | 33.5 | 41.8 | (22.9-70.2) |
| Female | 43 | 42.3 | 101.6 | (73.5-136.9) |  | Female | 74 | 113.8 | 65.0 | (51.1-81.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 67 | 42.4 | 157.9 | (122.4-200.6) |  |  |  |  |  |  |
| Female | 11 | 15.1 | 73.1 | (36.4-130.8) |  | Female | 116 | 124.1 | 93.4 | (77.2-112.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 248 | 221.6 | 111.9 | (98.4-126.7) |  | Male | 1657 | 1672.5 | 99.1 | (94.4-104.0) |
| Female | 258 | 254.8 | 101.3 | (89.3-114.4) |  | Female | 1735 | 1872.6 | 92.7 | (88.3-97.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

290

# Sterling

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 8.5 | 118.0 | (56.5-217.1) |  | Male | 5 | 5.7 | 87.4 | (28.2-203.9) |
| Female | 4 | 3.0 | nc | (nc-nc) |  | Female | 5 | 4.5 | 111.6 | (36.0-260.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 3 | 1.7 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 7 | 5.0 | 139.3 | (55.8-287.1) |
| Female | 34 | 35.3 | 96.4 | (66.8-134.8) |  | Female | 3 | 4.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.3 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 0 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 9.7 | 72.1 | (28.9-148.5) |  |  |  |  |  |  |
| Female | 7 | 9.5 | 73.7 | (29.5-151.8) |  | Female | 5 | 3.2 | 156.4 | (50.4-365.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 3 | 3.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 46 | 33.5 | 137.3 | (100.5-183.1) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 5.0 | 100.5 | (32.4-234.5) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 6 | 2.7 | 221.1 | (80.7-481.3) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 3.4 | 146.4 | (47.2-341.5) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 7 | 6.5 | 108.1 | (43.3-222.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 10 | 8.1 | 122.9 | (58.8-226.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 15.8 | 57.0 | (26.0-108.3) |  | Male | 120 | 119.2 | 100.7 | (83.5-120.4) |
| Female | 12 | 15.6 | 76.8 | (39.6-134.2) |  | Female | 107 | 116.6 | 91.8 | (75.2-110.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

291

# Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 5 | 2.1 | 234.5 | (75.6-547.3) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 5 | 1.6 | 314.3 | (101.3-733.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 1.9 | nc | (nc-nc) |
| Female | 10 | 12.7 | 78.5 | (37.6-144.4) |  | Female | 3 | 1.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 3.7 | 163.6 | (59.8-356.2) |  |  |  |  |  |  |
| Female | 6 | 3.8 | 156.0 | (57.0-339.5) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 0.9 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 1.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 13 | 12.9 | 100.6 | (53.5-172.1) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 4 | 3.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 6.5 | nc | (nc-nc) |  | Male | 47 | 45.5 | 103.3 | (75.9-137.4) |
| Female | 2 | 6.9 | nc | (nc-nc) |  | Female | 46 | 44.7 | 102.9 | (75.3-137.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

292

# Stoneham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 22 | 28.1 | 78.2 | (49.0-118.5) |  | Male | 13 | 17.4 | 74.6 | (39.7-127.6) |
| Female | 14 | 11.1 | 126.1 | (68.9-211.6) |  | Female | 19 | 14.2 | 133.8 | (80.5-208.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 4.7 | nc | (nc-nc) |  | Male | 6 | 5.2 | 115.8 | (42.3-252.0) |
| Female | 4 | 4.4 | nc | (nc-nc) |  | Female | 5 | 4.6 | 108.2 | (34.9-252.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 19 | 15.4 | 123.7 | (74.5-193.2) |
| Female | 127 | 108.8 | 116.7 | (97.3-138.8) |  | Female | 13 | 14.2 | 91.7 | (48.8-156.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 11.8 | 109.7 | (58.4-187.6) |
| Female | 9 | 3.6 | 253.2 | (115.5-480.6) |  | Female | 7 | 5.8 | 120.9 | (48.4-249.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 33 | 30.1 | 109.7 | (75.5-154.1) |  |  |  |  |  |  |
| Female | 34 | 33.5 | 101.6 | (70.4-142.0) |  | Female | 11 | 10.1 | 109.3 | (54.5-195.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 7.2 | 111.0 | (47.8-218.7) |  | Male | 3 | 9.4 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 13 | 10.9 | 119.4 | (63.5-204.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 1.9 | nc | (nc-nc) |  | Male | 79 | 94.4 | 83.7 | (66.3-104.3) |
| Female | 3 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 14.1 | 120.2 | (70.0-192.4) |  | Male | 12 | 6.4 | 187.3 | (96.7-327.3) |
| Female | 10 | 8.9 | 111.8 | (53.5-205.6) |  | Female | 5 | 4.3 | 117.6 | (37.9-274.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 4.0 | 151.8 | (55.4-330.3) |  | Male | 4 | 2.9 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 16 | 10.6 | 150.3 | (85.8-244.1) |  | Male | 11 | 6.1 | 178.9 | (89.2-320.2) |
| Female | 10 | 8.4 | 118.7 | (56.8-218.3) |  | Female | 23 | 18.5 | 124.6 | (78.9-186.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 8.9 | 89.6 | (38.6-176.5) |  |  |  |  |  |  |
| Female | 4 | 3.2 | nc | (nc-nc) |  | Female | 32 | 24.7 | 129.6 | (88.6-183.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 46 | 50.1 | 91.8 | (67.2-122.5) |  | Male | 368 | 357.7 | 102.9 | (92.6-113.9) |
| Female | 47 | 55.7 | 84.3 | (62.0-112.2) |  | Female | 418 | 381.8 | 109.5 | (99.2-120.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

293

# Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 28 | 31.3 | 89.5 | (59.4-129.3) |  | Male | 16 | 20.0 | 79.8 | (45.6-129.6) |
| Female | 13 | 12.3 | 105.6 | (56.2-180.6) |  | Female | 24 | 16.7 | 143.5 | (91.9-213.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 5.7 | 105.4 | (38.5-229.5) |  | Male | 4 | 5.9 | nc | (nc-nc) |
| Female | 6 | 5.1 | 116.5 | (42.6-253.7) |  | Female | 6 | 5.2 | 115.0 | (42.0-250.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 15 | 17.7 | 84.7 | (47.4-139.7) |
| Female | 142 | 129.2 | 109.9 | (92.6-129.6) |  | Female | 23 | 16.2 | 141.9 | (89.9-212.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 19 | 14.1 | 134.3 | (80.8-209.8) |
| Female | 5 | 4.3 | 115.0 | (37.1-268.5) |  | Female | 7 | 6.7 | 104.4 | (41.8-215.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 36 | 34.3 | 104.8 | (73.4-145.2) |  |  |  |  |  |  |
| Female | 43 | 37.2 | 115.7 | (83.7-155.9) |  | Female | 15 | 11.8 | 126.9 | (70.9-209.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 8.3 | 107.8 | (49.2-204.7) |  | Male | 11 | 10.6 | 103.5 | (51.6-185.2) |
| Female | 7 | 2.4 | 295.1 | (118.2-608.1) |  | Female | 16 | 12.0 | 133.3 | (76.1-216.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 2.3 | 214.1 | (69.0-499.5) |  | Male | 107 | 111.6 | 95.9 | (78.6-115.9) |
| Female | 6 | 2.0 | 301.0 | (109.9-655.1) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 23 | 16.7 | 137.5 | (87.2-206.4) |  | Male | 6 | 7.3 | 82.4 | (30.1-179.3) |
| Female | 16 | 10.4 | 153.5 | (87.7-249.3) |  | Female | 10 | 4.7 | 214.4 | (102.6-394.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 10 | 4.6 | 217.7 | (104.2-400.4) |  | Male | 3 | 3.8 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 12.2 | 65.4 | (28.1-128.8) |  | Male | 10 | 7.5 | 132.7 | (63.5-244.1) |
| Female | 6 | 9.6 | 62.6 | (22.9-136.3) |  | Female | 37 | 22.9 | 161.7 | (113.9-222.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 10.4 | 47.9 | (15.4-111.7) |  |  |  |  |  |  |
| Female | 1 | 3.7 | nc | (nc-nc) |  | Female | 22 | 29.6 | 74.4 | (46.6-112.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 68 | 56.5 | 120.3 | (93.4-152.5) |  | Male | 425 | 413.7 | 102.7 | (93.2-113.0) |
| Female | 63 | 63.8 | 98.7 | (75.8-126.3) |  | Female | 513 | 443.1 | 115.8 | (106.0-126.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

294

# Stow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 7.2 | 139.3 | (66.7-256.2) |  | Male | 3 | 4.8 | nc | (nc-nc) |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 3 | 3.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 4.2 | nc | (nc-nc) |
| Female | 32 | 29.1 | 109.8 | (75.1-155.0) |  | Female | 5 | 3.3 | 153.8 | (49.6-359.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 3.6 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 4 | 1.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 8.2 | 61.0 | (19.7-142.4) |  |  |  |  |  |  |
| Female | 6 | 7.0 | 85.1 | (31.1-185.3) |  | Female | 6 | 2.6 | 233.4 | (85.2-508.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 3 | 2.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 36 | 27.7 | 130.1 | (91.1-180.1) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 4.2 | nc | (nc-nc) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 3 | 2.2 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 2.9 | 172.1 | (55.5-401.7) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 2 | 5.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 9 | 6.7 | 134.7 | (61.4-255.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 13.3 | nc | (nc-nc) |  | Male | 91 | 99.7 | 91.2 | (73.5-112.0) |
| Female | 12 | 12.6 | 95.3 | (49.2-166.4) |  | Female | 100 | 93.2 | 107.3 | (87.3-130.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

295

# Sturbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 10.5 | 133.3 | (72.8-223.6) |  | Male | 9 | 6.8 | 131.6 | (60.0-249.8) |
| Female | 6 | 3.6 | 168.3 | (61.4-366.3) |  | Female | 6 | 5.2 | 115.3 | (42.1-251.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 4 | 6.0 | nc | (nc-nc) |
| Female | 42 | 40.5 | 103.7 | (74.8-140.2) |  | Female | 5 | 4.9 | 103.0 | (33.2-240.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.9 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 11.6 | 86.1 | (41.2-158.4) |  |  |  |  |  |  |
| Female | 5 | 10.8 | 46.1 | (14.9-107.7) |  | Female | 2 | 3.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  | Male | 4 | 3.6 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 6 | 3.5 | 173.7 | (63.4-378.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  | Male | 41 | 38.7 | 106.1 | (76.1-143.9) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 5.8 | 120.7 | (48.4-248.8) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 6 | 3.2 | 187.8 | (68.6-408.7) |  | Female | 2 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 4.2 | nc | (nc-nc) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 3 | 2.9 | nc | (nc-nc) |  | Female | 5 | 7.6 | 66.0 | (21.3-154.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 20 | 9.3 | 215.5 | (131.6-332.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 19.2 | 93.6 | (55.4-147.9) |  | Male | 137 | 141.5 | 96.9 | (81.3-114.5) |
| Female | 15 | 18.9 | 79.2 | (44.3-130.7) |  | Female | 139 | 135.3 | 102.7 | (86.4-121.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

296

# Sudbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 16 | 17.9 | 89.5 | (51.1-145.3) |  | Male | 21 | 12.0 | 174.5 | (108.0-266.8) |
| Female | 2 | 6.0 | nc | (nc-nc) |  | Female | 11 | 9.2 | 120.1 | (59.9-214.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 3.6 | 192.1 | (77.0-395.9) |  | Male | 4 | 3.6 | nc | (nc-nc) |
| Female | 3 | 2.9 | nc | (nc-nc) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 12 | 10.7 | 112.7 | (58.1-196.8) |
| Female | 112 | 74.2 | 150.9 | (124.2-181.6) |  | Female | 12 | 8.4 | 142.4 | (73.5-248.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 9.0 | nc | (nc-nc) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 2 | 3.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 22 | 20.6 | 106.6 | (66.8-161.5) |  |  |  |  |  |  |
| Female | 11 | 18.9 | 58.3 | (29.0-104.3) |  | Female | 5 | 6.6 | 76.2 | (24.6-177.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.0 | nc | (nc-nc) |  | Male | 7 | 6.2 | 112.1 | (44.9-231.0) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 4 | 5.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 76 | 68.4 | 111.1 | (87.5-139.0) |
| Female | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 10.5 | 105.2 | (52.4-188.2) |  | Male | 2 | 4.3 | nc | (nc-nc) |
| Female | 6 | 5.6 | 106.6 | (38.9-232.0) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 7.3 | 109.0 | (46.9-214.9) |  | Male | 5 | 4.8 | 104.2 | (33.6-243.2) |
| Female | 8 | 5.1 | 157.7 | (67.9-310.7) |  | Female | 15 | 13.8 | 108.3 | (60.6-178.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 6.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.9 | nc | (nc-nc) |  | Female | 14 | 16.6 | 84.3 | (46.0-141.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 33.1 | 33.3 | (16.6-59.5) |  | Male | 228 | 249.0 | 91.6 | (80.1-104.3) |
| Female | 35 | 32.0 | 109.2 | (76.1-151.9) |  | Female | 281 | 239.6 | 117.3 | (104.0-131.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

297

# Sunderland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 0 | 1.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 1.9 | nc | (nc-nc) |
| Female | 13 | 12.9 | 100.9 | (53.7-172.6) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 3.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 3.5 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 14 | 11.3 | 124.4 | (67.9-208.7) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 3.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 5.4 | nc | (nc-nc) |  | Male | 40 | 42.2 | 94.7 | (67.6-129.0) |
| Female | 1 | 5.7 | nc | (nc-nc) |  | Female | 24 | 43.6 | 55.0 | (35.3-81.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

298

# Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 8.7 | 115.3 | (55.2-212.0) |  | Male | 10 | 6.1 | 163.4 | (78.2-300.5) |
| Female | 5 | 2.7 | 182.9 | (58.9-426.8) |  | Female | 4 | 4.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 3 | 1.8 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 7 | 5.4 | 130.3 | (52.2-268.5) |
| Female | 40 | 36.7 | 108.9 | (77.8-148.3) |  | Female | 5 | 4.0 | 124.5 | (40.1-290.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 4.8 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 5 | 1.8 | 285.4 | (92.0-666.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 10.2 | 68.3 | (27.4-140.7) |  |  |  |  |  |  |
| Female | 8 | 8.6 | 92.9 | (40.0-183.0) |  | Female | 1 | 3.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.6 | nc | (nc-nc) |  | Male | 1 | 3.1 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 30 | 36.8 | 81.6 | (55.0-116.5) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 5.5 | 127.7 | (51.2-263.2) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 5 | 2.7 | 183.2 | (59.0-427.5) |  | Female | 2 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 3.6 | 138.0 | (44.5-322.1) |  | Male | 3 | 2.6 | nc | (nc-nc) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 8 | 7.3 | 109.2 | (47.0-215.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 14 | 8.4 | 166.2 | (90.8-278.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 16.5 | 103.2 | (60.1-165.3) |  | Male | 123 | 127.8 | 96.2 | (80.0-114.8) |
| Female | 13 | 15.2 | 85.8 | (45.6-146.7) |  | Female | 123 | 116.2 | 105.8 | (88.0-126.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

299

# Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 22 | 18.1 | 121.7 | (76.2-184.2) |  | Male | 11 | 11.1 | 98.8 | (49.2-176.8) |
| Female | 14 | 7.1 | 198.4 | (108.4-333.0) |  | Female | 12 | 9.1 | 131.9 | (68.1-230.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.1 | nc | (nc-nc) |  | Male | 2 | 3.3 | nc | (nc-nc) |
| Female | 3 | 2.8 | nc | (nc-nc) |  | Female | 4 | 2.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 19 | 9.9 | 192.2 | (115.7-300.2) |
| Female | 83 | 70.6 | 117.6 | (93.6-145.7) |  | Female | 12 | 9.1 | 132.5 | (68.4-231.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 7.7 | 77.7 | (28.4-169.1) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 19.5 | 87.4 | (50.9-139.9) |  |  |  |  |  |  |
| Female | 25 | 21.6 | 115.7 | (74.8-170.7) |  | Female | 5 | 6.5 | 76.6 | (24.7-178.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 4.7 | nc | (nc-nc) |  | Male | 4 | 6.0 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 7 | 7.0 | 100.2 | (40.1-206.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 58 | 61.0 | 95.0 | (72.2-122.8) |
| Female | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 9.1 | 120.9 | (60.3-216.3) |  | Male | 2 | 4.1 | nc | (nc-nc) |
| Female | 7 | 5.7 | 122.7 | (49.2-252.8) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 6.9 | 86.9 | (31.7-189.2) |  | Male | 8 | 3.9 | 204.8 | (88.2-403.5) |
| Female | 10 | 5.4 | 184.7 | (88.4-339.7) |  | Female | 15 | 11.9 | 126.5 | (70.7-208.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 5.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 23 | 16.1 | 143.2 | (90.7-214.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 32 | 31.9 | 100.3 | (68.6-141.5) |  | Male | 226 | 230.3 | 98.2 | (85.8-111.8) |
| Female | 36 | 34.7 | 103.8 | (72.7-143.7) |  | Female | 287 | 245.0 | 117.1 | (104.0-131.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

300

# Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 20 | 20.3 | 98.7 | (60.2-152.4) |  | Male | 9 | 12.9 | 69.8 | (31.8-132.5) |
| Female | 13 | 7.4 | 176.3 | (93.8-301.4) |  | Female | 4 | 9.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.6 | nc | (nc-nc) |  | Male | 2 | 3.8 | nc | (nc-nc) |
| Female | 5 | 3.0 | 164.5 | (53.0-383.9) |  | Female | 3 | 3.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 12 | 11.4 | 105.3 | (54.4-184.0) |
| Female | 75 | 77.3 | 97.0 | (76.3-121.6) |  | Female | 6 | 9.7 | 62.0 | (22.6-134.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 9.2 | 87.4 | (37.6-172.3) |
| Female | 5 | 2.6 | 193.1 | (62.2-450.5) |  | Female | 2 | 4.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 22.1 | 77.0 | (44.8-123.3) |  |  |  |  |  |  |
| Female | 19 | 22.3 | 85.1 | (51.2-132.9) |  | Female | 8 | 7.1 | 113.3 | (48.8-223.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 5.4 | 129.1 | (51.7-266.0) |  | Male | 5 | 6.9 | 72.7 | (23.4-169.6) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 8 | 7.2 | 111.0 | (47.8-218.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 1.4 | nc | (nc-nc) |  | Male | 89 | 72.9 | 122.0 | (98.0-150.1) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 10.8 | 139.2 | (77.8-229.6) |  | Male | 5 | 4.7 | 106.1 | (34.2-247.5) |
| Female | 4 | 6.2 | nc | (nc-nc) |  | Female | 3 | 2.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.0 | nc | (nc-nc) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 7.8 | nc | (nc-nc) |  | Male | 1 | 4.8 | nc | (nc-nc) |
| Female | 5 | 5.7 | 88.0 | (28.4-205.4) |  | Female | 9 | 13.5 | 66.7 | (30.4-126.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 6.8 | 88.4 | (32.3-192.5) |  |  |  |  |  |  |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 17 | 17.7 | 95.8 | (55.8-153.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 28 | 36.5 | 76.6 | (50.9-110.8) |  | Male | 261 | 267.5 | 97.6 | (86.1-110.2) |
| Female | 36 | 37.8 | 95.2 | (66.7-131.9) |  | Female | 248 | 264.4 | 93.8 | (82.5-106.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

301

# Taunton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 53 | 55.2 | 96.0 | (71.9-125.6) |  | Male | 26 | 36.6 | 71.1 | (46.4-104.2) |
| Female | 25 | 21.5 | 116.1 | (75.1-171.4) |  | Female | 29 | 31.3 | 92.5 | (62.0-132.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 10.9 | 82.7 | (37.7-157.0) |  | Male | 10 | 10.6 | 94.4 | (45.2-173.7) |
| Female | 6 | 9.7 | 62.0 | (22.7-135.0) |  | Female | 16 | 9.2 | 174.8 | (99.9-283.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 1.8 | nc | (nc-nc) |  | Male | 40 | 32.4 | 123.6 | (88.3-168.3) |
| Female | 242 | 234.3 | 103.3 | (90.7-117.1) |  | Female | 41 | 28.9 | 141.7 | (101.7-192.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 32 | 25.9 | 123.7 | (84.6-174.6) |
| Female | 7 | 8.5 | 82.7 | (33.1-170.5) |  | Female | 10 | 12.0 | 83.3 | (39.9-153.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 74 | 61.9 | 119.5 | (93.9-150.1) |  |  |  |  |  |  |
| Female | 90 | 66.3 | 135.7 | (109.1-166.8) |  | Female | 19 | 21.4 | 88.6 | (53.3-138.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 17 | 14.8 | 114.8 | (66.9-183.9) |  | Male | 28 | 18.9 | 148.5 | (98.7-214.7) |
| Female | 3 | 4.1 | nc | (nc-nc) |  | Female | 25 | 21.1 | 118.7 | (76.8-175.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 9 | 4.8 | 188.5 | (86.0-357.8) |  | Male | 183 | 196.7 | 93.0 | (80.1-107.5) |
| Female | 6 | 4.1 | 145.6 | (53.2-316.8) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 31 | 30.6 | 101.3 | (68.8-143.8) |  | Male | 17 | 13.0 | 130.5 | (76.0-209.0) |
| Female | 26 | 18.7 | 139.4 | (91.0-204.2) |  | Female | 7 | 8.3 | 83.9 | (33.6-172.9) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 14 | 8.2 | 170.7 | (93.3-286.5) |  | Male | 11 | 8.3 | 132.1 | (65.8-236.3) |
| Female | 3 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 19 | 22.5 | 84.5 | (50.9-132.0) |  | Male | 15 | 14.6 | 103.0 | (57.6-169.9) |
| Female | 13 | 17.6 | 73.9 | (39.3-126.5) |  | Female | 75 | 45.5 | 164.9 | (129.7-206.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 20 | 18.9 | 105.8 | (64.6-163.5) |  |  |  |  |  |  |
| Female | 5 | 6.5 | 77.4 | (24.9-180.7) |  | Female | 47 | 52.6 | 89.3 | (65.6-118.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 133 | 99.7 | 133.4 | (111.7-158.1) |  | Male | 807 | 743.2 | 108.6 | (101.2-116.3) |
| Female | 122 | 110.7 | 110.2 | (91.5-131.6) |  | Female | 885 | 799.1 | 110.7 | (103.6-118.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

302

# Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 9.0 | 122.0 | (60.8-218.3) |  | Male | 5 | 6.0 | 83.0 | (26.7-193.7) |
| Female | 3 | 2.9 | nc | (nc-nc) |  | Female | 0 | 4.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 1.8 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 3 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 5.3 | 94.2 | (30.4-219.9) |
| Female | 28 | 32.5 | 86.0 | (57.1-124.3) |  | Female | 4 | 3.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 4.4 | nc | (nc-nc) |
| Female | 3 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 10.2 | 88.4 | (40.3-167.8) |  |  |  |  |  |  |
| Female | 13 | 8.9 | 146.2 | (77.8-250.0) |  | Female | 6 | 3.0 | 203.2 | (74.2-442.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.5 | nc | (nc-nc) |  | Male | 4 | 3.1 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 29 | 34.5 | 84.2 | (56.4-120.9) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 5.2 | 135.0 | (54.1-278.2) |  | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 3.6 | nc | (nc-nc) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 4 | 6.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 8 | 7.4 | 108.6 | (46.8-214.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 16.7 | 107.9 | (63.9-170.5) |  | Male | 115 | 124.6 | 92.3 | (76.2-110.8) |
| Female | 24 | 15.1 | 158.8 | (101.7-236.3) |  | Female | 110 | 109.3 | 100.6 | (82.7-121.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

303

# Tewksbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 44 | 32.3 | 136.1 | (98.9-182.8) |  | Male | 20 | 21.2 | 94.2 | (57.5-145.4) |
| Female | 11 | 11.6 | 94.7 | (47.2-169.5) |  | Female | 16 | 16.9 | 94.9 | (54.2-154.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 6.1 | 114.5 | (45.9-235.9) |  | Male | 6 | 6.2 | 96.2 | (35.1-209.4) |
| Female | 4 | 5.2 | nc | (nc-nc) |  | Female | 5 | 5.0 | 100.0 | (32.2-233.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.0 | nc | (nc-nc) |  | Male | 15 | 18.7 | 80.3 | (44.9-132.4) |
| Female | 136 | 131.8 | 103.2 | (86.6-122.1) |  | Female | 18 | 15.8 | 114.2 | (67.6-180.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 14 | 15.3 | 91.5 | (50.0-153.6) |
| Female | 7 | 4.6 | 153.1 | (61.4-315.5) |  | Female | 8 | 6.6 | 120.6 | (51.9-237.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 35 | 36.0 | 97.1 | (67.6-135.1) |  |  |  |  |  |  |
| Female | 29 | 35.4 | 82.0 | (54.9-117.8) |  | Female | 15 | 11.9 | 126.0 | (70.5-207.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 8.9 | 113.0 | (54.1-207.8) |  | Male | 15 | 11.1 | 134.9 | (75.5-222.6) |
| Female | 4 | 2.2 | nc | (nc-nc) |  | Female | 11 | 11.2 | 97.8 | (48.8-175.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 2.5 | nc | (nc-nc) |  | Male | 117 | 119.6 | 97.8 | (80.9-117.2) |
| Female | 3 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 29 | 18.0 | 161.1 | (107.8-231.3) |  | Male | 6 | 7.6 | 78.7 | (28.7-171.3) |
| Female | 9 | 10.3 | 87.0 | (39.7-165.2) |  | Female | 8 | 4.4 | 181.5 | (78.1-357.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 4.9 | 122.3 | (44.7-266.2) |  | Male | 6 | 4.0 | 148.3 | (54.2-322.9) |
| Female | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 22 | 12.8 | 171.7 | (107.6-260.0) |  | Male | 7 | 8.2 | 84.9 | (34.0-175.0) |
| Female | 15 | 9.3 | 161.7 | (90.4-266.6) |  | Female | 26 | 24.3 | 106.9 | (69.8-156.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 11.2 | 71.2 | (30.7-140.4) |  |  |  |  |  |  |
| Female | 1 | 3.6 | nc | (nc-nc) |  | Female | 35 | 30.2 | 115.8 | (80.7-161.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 62 | 59.3 | 104.6 | (80.2-134.1) |  | Male | 469 | 438.0 | 107.1 | (97.6-117.2) |
| Female | 88 | 61.5 | 143.1 | (114.8-176.3) |  | Female | 493 | 439.6 | 112.2 | (102.5-122.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

304

# Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 4.7 | nc | (nc-nc) |  | Male | 5 | 3.0 | 164.5 | (53.0-383.8) |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 4 | 2.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 2.7 | nc | (nc-nc) |
| Female | 31 | 19.6 | 157.9 | (107.3-224.1) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 2 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 5.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 6 | 5.6 | 107.1 | (39.1-233.1) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 4 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.4 | nc | (nc-nc) |  | Male | 20 | 17.2 | 116.4 | (71.1-179.8) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.6 | nc | (nc-nc) |  | Male | 3 | 1.1 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 2 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 2 | 3.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 5 | 4.6 | 108.6 | (35.0-253.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 8.4 | nc | (nc-nc) |  | Male | 71 | 62.9 | 113.0 | (88.2-142.5) |
| Female | 8 | 9.7 | 82.3 | (35.4-162.1) |  | Female | 74 | 67.3 | 109.9 | (86.3-138.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

305

# Tolland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 2.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 6 | 10.1 | 59.3 | (21.6-129.0) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 2 | 7.2 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

306

# Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 8.0 | 99.7 | (42.9-196.5) |  | Male | 2 | 5.0 | nc | (nc-nc) |
| Female | 3 | 3.0 | nc | (nc-nc) |  | Female | 6 | 3.8 | 158.9 | (58.0-345.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 7 | 4.4 | 157.6 | (63.1-324.7) |
| Female | 33 | 30.0 | 109.9 | (75.7-154.4) |  | Female | 4 | 3.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.6 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 8.7 | 57.2 | (18.4-133.4) |  |  |  |  |  |  |
| Female | 7 | 9.0 | 77.4 | (31.0-159.4) |  | Female | 5 | 2.7 | 182.2 | (58.7-425.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 1 | 2.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 2.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 36 | 28.4 | 127.0 | (88.9-175.8) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 4.2 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 3 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 3.1 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 3 | 4.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 8 | 6.8 | 118.2 | (50.9-233.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 12 | 14.4 | 83.1 | (42.9-145.2) |  | Male | 103 | 104.5 | 98.6 | (80.5-119.6) |
| Female | 15 | 14.6 | 102.4 | (57.3-169.0) |  | Female | 106 | 103.1 | 102.8 | (84.2-124.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

307

# Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 7.8 | 140.8 | (70.2-251.9) |  | Male | 5 | 5.7 | 88.0 | (28.4-205.4) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 7 | 4.5 | 155.3 | (62.2-320.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 8 | 5.0 | 160.3 | (69.0-315.9) |
| Female | 34 | 35.4 | 95.9 | (66.4-134.0) |  | Female | 3 | 3.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 4.5 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 9.4 | 137.8 | (73.3-235.7) |  |  |  |  |  |  |
| Female | 12 | 8.3 | 144.9 | (74.8-253.1) |  | Female | 6 | 3.2 | 190.2 | (69.5-414.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 2.4 | 208.9 | (67.3-487.4) |  | Male | 1 | 2.9 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 2.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  | Male | 18 | 33.9 | 53.1 | (31.5-83.9) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 5.1 | 97.9 | (31.6-228.6) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 5 | 2.6 | 191.8 | (61.8-447.6) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 3.4 | nc | (nc-nc) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 8 | 7.3 | 110.0 | (47.4-216.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 5 | 8.2 | 61.3 | (19.7-143.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 14.9 | 120.4 | (71.3-190.3) |  | Male | 109 | 118.0 | 92.4 | (75.8-111.4) |
| Female | 15 | 14.2 | 105.7 | (59.1-174.3) |  | Female | 114 | 111.8 | 102.0 | (84.1-122.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

308

# Truro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 3.8 | nc | (nc-nc) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 18 | 12.5 | 144.5 | (85.6-228.4) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 4.0 | 124.8 | (40.2-291.3) |  |  |  |  |  |  |
| Female | 3 | 3.3 | nc | (nc-nc) |  | Female | 4 | 1.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 1.0 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 8 | 14.4 | 55.5 | (23.9-109.4) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 4 | 3.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 7.0 | nc | (nc-nc) |  | Male | 35 | 49.9 | 70.1 | (48.8-97.5) |
| Female | 4 | 6.3 | nc | (nc-nc) |  | Female | 52 | 41.9 | 124.0 | (92.6-162.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

309

# Tyngsborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 9.0 | 156.0 | (85.2-261.8) |  | Male | 7 | 6.7 | 105.2 | (42.1-216.7) |
| Female | 5 | 3.2 | 157.8 | (50.9-368.3) |  | Female | 6 | 5.6 | 107.4 | (39.2-233.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 2 | 5.9 | nc | (nc-nc) |
| Female | 32 | 43.7 | 73.3 | (50.1-103.4) |  | Female | 3 | 4.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 5.3 | 95.2 | (30.7-222.1) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 3 | 2.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 11.1 | 108.1 | (55.8-188.8) |  |  |  |  |  |  |
| Female | 8 | 10.2 | 78.1 | (33.6-154.0) |  | Female | 4 | 3.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 2 | 3.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 31 | 37.8 | 82.1 | (55.8-116.5) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 6.0 | 83.9 | (27.0-195.8) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 2 | 3.2 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 4.0 | 151.9 | (55.5-330.5) |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 4 | 2.8 | nc | (nc-nc) |  | Female | 10 | 9.2 | 108.4 | (51.9-199.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 3.7 | 214.7 | (92.5-423.1) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 8 | 9.7 | 82.2 | (35.4-161.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 22 | 17.0 | 129.6 | (81.2-196.2) |  | Male | 139 | 135.7 | 102.4 | (86.1-121.0) |
| Female | 22 | 17.4 | 126.5 | (79.3-191.6) |  | Female | 126 | 137.6 | 91.6 | (76.3-109.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

310

# Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 3 | 2.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 3 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 1.3 | nc | (nc-nc) |  | Male | 8 | 9.0 | 89.4 | (38.5-176.1) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 6 | 7.6 | 78.9 | (28.8-171.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

311

# Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 6.5 | 108.4 | (43.4-223.4) |  | Male | 4 | 4.7 | nc | (nc-nc) |
| Female | 4 | 2.3 | nc | (nc-nc) |  | Female | 2 | 3.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 4 | 1.3 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 7 | 4.1 | 170.3 | (68.2-350.8) |
| Female | 36 | 30.1 | 119.6 | (83.7-165.6) |  | Female | 2 | 3.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 3.6 | 138.5 | (44.6-323.3) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 7.8 | 76.8 | (28.0-167.1) |  |  |  |  |  |  |
| Female | 3 | 7.3 | nc | (nc-nc) |  | Female | 4 | 2.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 1.9 | nc | (nc-nc) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 4 | 2.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 18 | 26.2 | 68.7 | (40.7-108.6) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 4.1 | nc | (nc-nc) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 2.8 | nc | (nc-nc) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 4 | 6.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 2.6 | 196.0 | (63.1-457.3) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 9 | 6.7 | 134.4 | (61.3-255.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 13 | 12.1 | 107.3 | (57.1-183.5) |  | Male | 86 | 94.9 | 90.6 | (72.4-111.9) |
| Female | 12 | 12.4 | 96.6 | (49.9-168.8) |  | Female | 99 | 95.7 | 103.4 | (84.0-125.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

312

# Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 13.4 | 89.2 | (46.1-155.9) |  | Male | 13 | 9.2 | 141.8 | (75.4-242.5) |
| Female | 6 | 4.7 | 127.7 | (46.6-278.0) |  | Female | 5 | 7.2 | 69.8 | (22.5-162.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.7 | nc | (nc-nc) |  | Male | 4 | 2.7 | nc | (nc-nc) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 9 | 8.1 | 111.0 | (50.7-210.7) |
| Female | 63 | 55.7 | 113.2 | (87.0-144.8) |  | Female | 4 | 6.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 6.7 | 178.1 | (91.9-311.0) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 1 | 2.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 15.5 | 109.6 | (63.8-175.5) |  |  |  |  |  |  |
| Female | 16 | 14.6 | 109.8 | (62.7-178.3) |  | Female | 3 | 5.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 3.7 | nc | (nc-nc) |  | Male | 6 | 4.7 | 128.3 | (46.9-279.4) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 5 | 4.6 | 109.9 | (35.4-256.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 60 | 50.4 | 119.1 | (90.9-153.4) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 7.9 | 101.7 | (43.8-200.5) |  | Male | 4 | 3.2 | nc | (nc-nc) |
| Female | 6 | 4.3 | 139.3 | (50.9-303.2) |  | Female | 0 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  | Male | 4 | 2.0 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 5.5 | 108.1 | (39.5-235.4) |  | Male | 4 | 3.8 | nc | (nc-nc) |
| Female | 6 | 3.9 | 154.0 | (56.2-335.2) |  | Female | 9 | 10.8 | 83.3 | (38.0-158.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 4.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 16 | 12.5 | 128.2 | (73.2-208.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 31 | 24.6 | 126.0 | (85.6-178.8) |  | Male | 221 | 186.8 | 118.3 | (103.2-135.0) |
| Female | 24 | 25.0 | 96.2 | (61.6-143.1) |  | Female | 190 | 183.4 | 103.6 | (89.4-119.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

313

# Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 31 | 27.8 | 111.5 | (75.7-158.2) |  | Male | 22 | 18.1 | 121.8 | (76.3-184.4) |
| Female | 8 | 10.4 | 76.9 | (33.1-151.5) |  | Female | 27 | 14.8 | 182.5 | (120.2-265.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 5.2 | 135.0 | (54.1-278.2) |  | Male | 4 | 5.3 | nc | (nc-nc) |
| Female | 5 | 4.5 | 110.4 | (35.6-257.7) |  | Female | 3 | 4.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 11 | 16.0 | 68.9 | (34.4-123.3) |
| Female | 124 | 112.9 | 109.8 | (91.3-130.9) |  | Female | 23 | 13.9 | 165.5 | (104.9-248.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 12.7 | 94.1 | (48.6-164.5) |
| Female | 4 | 4.0 | nc | (nc-nc) |  | Female | 3 | 5.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 37 | 30.7 | 120.4 | (84.7-165.9) |  |  |  |  |  |  |
| Female | 36 | 31.9 | 112.9 | (79.0-156.3) |  | Female | 6 | 10.3 | 58.2 | (21.3-126.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 7.4 | 107.8 | (46.4-212.5) |  | Male | 7 | 9.4 | 74.3 | (29.7-153.0) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 10 | 10.2 | 98.3 | (47.1-180.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 82 | 98.6 | 83.2 | (66.2-103.2) |
| Female | 0 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 15.1 | 53.1 | (22.9-104.7) |  | Male | 4 | 6.5 | nc | (nc-nc) |
| Female | 8 | 9.0 | 89.1 | (38.4-175.6) |  | Female | 2 | 4.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 4.1 | 121.8 | (39.2-284.2) |  | Male | 5 | 3.6 | 137.3 | (44.2-320.4) |
| Female | 2 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 11.0 | 100.0 | (49.8-178.9) |  | Male | 6 | 6.9 | 86.5 | (31.6-188.2) |
| Female | 7 | 8.3 | 84.4 | (33.8-173.9) |  | Female | 25 | 21.0 | 118.9 | (76.9-175.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 9.4 | 53.0 | (17.1-123.8) |  |  |  |  |  |  |
| Female | 5 | 3.1 | 159.8 | (51.5-373.0) |  | Female | 16 | 25.6 | 62.5 | (35.7-101.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 42 | 50.1 | 83.8 | (60.4-113.3) |  | Male | 335 | 369.4 | 90.7 | (81.2-100.9) |
| Female | 53 | 53.6 | 98.9 | (74.1-129.4) |  | Female | 396 | 383.5 | 103.3 | (93.3-113.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

314

# Wales

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 2 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 8 | 7.6 | 105.2 | (45.3-207.2) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 6 | 1.8 | 333.5 | (121.8-725.9) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 8.1 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 5 | 1.8 | 276.1 | (89.0-644.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 3.8 | 132.5 | (42.7-309.2) |  | Male | 26 | 28.6 | 91.0 | (59.5-133.4) |
| Female | 5 | 3.2 | 154.3 | (49.7-360.2) |  | Female | 32 | 24.4 | 131.3 | (89.8-185.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

315